SEC Comment Letter for ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Nov 14, 2018
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Nov. 14, 2018 · CIK: 0001612940 · Accession: 0000000000-18-035330
AI Filing Summary & Sentiment
File numbers found in text: 333-228251
Letter
November 14, 2018 Daniel de Boer Chief Executive Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Re:ProQR Therapeutics N.V. Registration Statement on Form F-3 Filed November 7, 2018 File No. 333-228251 Dear Mr. de Boer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Danielle M. Lauzon
Show Raw Text
November 14, 2018
Daniel de Boer
Chief Executive Officer
ProQR Therapeutics N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Re:ProQR Therapeutics N.V.
Registration Statement on Form F-3
Filed November 7, 2018
File No. 333-228251
Dear Mr. de Boer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Danielle M. Lauzon